The released batch was manufactured at Everest's Jiashan manufacturing site using the Company's proprietary mRNA platform, in compliance with global GMP standards. EVM14 is an off-the-shelf ...

A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent ...

Using a newly discovered byproduct of dying cancer cells, University of Wisconsin–Madison researchers are developing ...

Geneos incorporates up to 40 antigens into their personalized therapeutic cancer vaccines, or PTCVs. Targetable neoantigens are identified by comparing gene expression between the tumor biopsy and ...

These features are called antigens, and when they're introduced ... Vinod Balachandran, director of the Olayan Center for ...

While research in mice has shown encouraging results, the next phases of human trials will need to confirm safety and ...

We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to move ...

US researchers have found that developing personalised vaccines can play a key role in keeping aggressive tumours from ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

For decades, vaccines have been seen as tools to prevent disease, protecting us from measles, flu, and even certain types of ...

EVM14, an mRNA cancer vaccine, received FDA clearance for investigational new drug application, advancing Everest's mRNA technology to global clinical trials. Preclinical studies showed EVM14 induces ...

A vaccine that could help fight one of the deadliest forms of cancer is in the works - and could one day become a reality.